The Pediatric Infectious Disease Journal · 1989 · 41 citations · 0 references
MedicinePediatricsPharmacotherapyAntimicrobial PharmacotherapyMusculoskeletal InfectionPediatric Infectious DiseasesBacterial InfectionsBone InfectionsOsteomyelitisPediatric Antibiotic TherapyPediatric Antimicrobial TherapyPediatric Musculoskeletal InfectionBacterial Musculoskeletal InfectionBacterial Soft Tissue InfectionCeftriaxone TherapyOsteomyelitis Antibiotic ManagementPediatric Infection TreatmentPediatric Musculoskeletal Infection TherapySoft Tissue Infection Antibiotic TherapyStaphylococcus Aureus Musculoskeletal Infection
In a prospective study 105 children hospitalized with soft tissue infection, 11 children with suppurative arthritis and 9 children with osteomyelitis were treated with either parenterally administered ampicillin/sulbactam or ceftriaxone. Treatment was randomized using a computer-generated table in a 2:1 fashion: 84 patients received ampicillin/sulbactam and 41 patients received ceftriaxone. Organisms isolated from wound site or blood cultures included Staphylococcus aureus (33), Streptococcus pyogenes (19), Haemophilus influenzae (9) including 4 beta-lactamase-positive organisms, Streptococcus pneumoniae (5), Neisseria gonorrhoeae (3) and 9 other organisms. Clinical and bacteriologic response was satisfactory in 100% of the ampicillin/sulbactam-treated patients and in 93% of the ceftriaxone-treated patients. Two patients with S. aureus infections treated with ceftriaxone had a delayed response and required change in therapy to parenterally administered oxacillin. Ampicillin/sulbactam represents a potentially useful single agent for the treatment of cellulitis and bone or joint infections in pediatric patients.